Abstract
Because of adverse reactions, early efforts to introduce high affinity competitive or use-dependent NMDA receptor antagonists into patients suffering from stroke, head trauma or epilepsy met with failure. Later it was discovered that both low affinity use-dependent NMDA receptor antagonists and compounds with selective affinity for the NR2B receptor subunit met the criteria for safe administration into patients. Furthermore, these low affinity antagonists exhibit significant mechanistic differences from their higher affinity counterparts. Success of the latter is attested to the ability of the following low affinity compounds to be marketed: 1) Cough suppressant - dextromethorphan (available for decades) 2) Parkinsons disease - amantadine, memantine and budipine 3) Dementia - memantine and 4) Epilepsy - felbamate. Moreover, Phase III clinical trials are ongoing with remacemide for epilepsy and Huntingtons disease and head trauma for HU-211. A host of compounds are or were under evaluation for the pos sible treatment of stroke, head trauma, hyperalgesia and various neurodegenerative disorders. Despite the fact that other drugs with associated NMDA receptor mechanisms have reached clinical status, this review focuses only on those competitive and use-dependent NMDA receptor antagonists that reached clinical trails. The ensuing discussions link the in vivo pharmacological investigations that led to the success / mistakes / failures for eventual testing of promising compounds in the clinic.
Keywords: NMDA Receptor, Neuropathologies, NR1 / NR2A receptor, transient neuronal vacuoles, CPPene, Dextromethorphan, Felbamate, Selfotel, MK801, STROKE PRECLINICAL, TRAUMATIC BRAIN INJURY (TBI)
Current Drug Targets
Title: Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Volume: 2 Issue: 3
Author(s): Gene C. Palmer
Affiliation:
Keywords: NMDA Receptor, Neuropathologies, NR1 / NR2A receptor, transient neuronal vacuoles, CPPene, Dextromethorphan, Felbamate, Selfotel, MK801, STROKE PRECLINICAL, TRAUMATIC BRAIN INJURY (TBI)
Abstract: Because of adverse reactions, early efforts to introduce high affinity competitive or use-dependent NMDA receptor antagonists into patients suffering from stroke, head trauma or epilepsy met with failure. Later it was discovered that both low affinity use-dependent NMDA receptor antagonists and compounds with selective affinity for the NR2B receptor subunit met the criteria for safe administration into patients. Furthermore, these low affinity antagonists exhibit significant mechanistic differences from their higher affinity counterparts. Success of the latter is attested to the ability of the following low affinity compounds to be marketed: 1) Cough suppressant - dextromethorphan (available for decades) 2) Parkinsons disease - amantadine, memantine and budipine 3) Dementia - memantine and 4) Epilepsy - felbamate. Moreover, Phase III clinical trials are ongoing with remacemide for epilepsy and Huntingtons disease and head trauma for HU-211. A host of compounds are or were under evaluation for the pos sible treatment of stroke, head trauma, hyperalgesia and various neurodegenerative disorders. Despite the fact that other drugs with associated NMDA receptor mechanisms have reached clinical status, this review focuses only on those competitive and use-dependent NMDA receptor antagonists that reached clinical trails. The ensuing discussions link the in vivo pharmacological investigations that led to the success / mistakes / failures for eventual testing of promising compounds in the clinic.
Export Options
About this article
Cite this article as:
Palmer C. Gene, Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies, Current Drug Targets 2001; 2 (3) . https://dx.doi.org/10.2174/1389450013348335
DOI https://dx.doi.org/10.2174/1389450013348335 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Adult Neurogenesis and the Diseased Brain
Current Medicinal Chemistry Casein Kinase 2 Affects Epilepsy by Regulating Ion Channels: A Potential Mechanism
CNS & Neurological Disorders - Drug Targets Neurochemical Imbalance in Epilepsy from Animal Model to Human
Current Psychopharmacology Critical Role of the Endocannabinoid System in the Regulation of Food Intake and Energy Metabolism, with Phylogenetic, Developmental, and Pathophysiological Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia
Mini-Reviews in Medicinal Chemistry Natural Products as a Source of CNS-Active Agents
Mini-Reviews in Organic Chemistry Breath-Holding Spells in Pediatrics: A Narrative Review of the Current Evidence
Current Pediatric Reviews Conotoxin Superfamily Prediction Using Diffusion Maps Dimensionality Reduction and Subspace Classifier
Current Protein & Peptide Science Application of Artificial Intelligence in Pharmaceutical and Biomedical Studies
Current Pharmaceutical Design Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Cellular Functions of Vaults and their Involvement in Multidrug Resistance
Current Drug Targets Allosteric Modulators of GABAB Receptors: Mechanism of Action and Therapeutic Perspective
Current Neuropharmacology Recent Developments in Anxiety Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Davunetide: Peptide Therapeutic in Neurological Disorders
Current Medicinal Chemistry The Role of Orexin System in Antipsychotics Induced Weight Gain
Current Psychiatry Reviews CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective
Current Stem Cell Research & Therapy Piperine: A Comprehensive Review of Pre-Clinical and Clinical Investigations
Current Bioactive Compounds Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design α7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson’s Disease
Current Drug Targets